Mallinckrodt PLC (NYSE:MNK) General Counsel Michael-Bryant Hicks acquired 7,900 shares of Mallinckrodt PLC stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $20.80 per share, with a total value of $164,320.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Mallinckrodt PLC (NYSE MNK) opened at $21.90 on Tuesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. The firm has a market cap of $2,067.31, a PE ratio of 2.94, a price-to-earnings-growth ratio of 0.33 and a beta of 1.46. Mallinckrodt PLC has a 12 month low of $19.00 and a 12 month high of $68.12.
Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.17. Mallinckrodt PLC had a net margin of 11.43% and a return on equity of 14.79%. The business had revenue of $793.90 million during the quarter, compared to analyst estimates of $808.93 million. During the same quarter last year, the firm posted $2.04 earnings per share. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. equities analysts forecast that Mallinckrodt PLC will post 7.23 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Mallinckrodt PLC (MNK) General Counsel Michael-Bryant Hicks Buys 7,900 Shares” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/14/mallinckrodt-plc-mnk-general-counsel-michael-bryant-hicks-buys-7900-shares.html.
Several hedge funds and other institutional investors have recently bought and sold shares of MNK. Denali Advisors LLC purchased a new position in shares of Mallinckrodt PLC in the second quarter valued at approximately $112,000. Sterling Capital Management LLC purchased a new position in shares of Mallinckrodt PLC in the second quarter valued at approximately $204,000. Advisor Partners LLC purchased a new position in shares of Mallinckrodt PLC in the second quarter valued at approximately $242,000. Municipal Employees Retirement System of Michigan boosted its stake in shares of Mallinckrodt PLC by 24.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,640 shares of the company’s stock valued at $253,000 after purchasing an additional 1,110 shares during the period. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Mallinckrodt PLC in the second quarter valued at approximately $260,000. 98.83% of the stock is owned by institutional investors and hedge funds.
MNK has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their price objective on shares of Mallinckrodt PLC from $70.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. Zacks Investment Research cut shares of Mallinckrodt PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Deutsche Bank AG set a $56.00 price objective on shares of Mallinckrodt PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $67.00 target price on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research report on Saturday, October 21st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Mallinckrodt PLC in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $48.14.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.